Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-25-035191
Filing Date
2025-11-14
Accepted
2025-11-14 16:11:54
Documents
49
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q gnpx20250930_10q.htm   iXBRL 10-Q 1152028
2 EXHIBIT 31.1 ex_857061.htm EX-31.1 16157
3 EXHIBIT 31.2 ex_857062.htm EX-31.2 14654
4 EXHIBIT 32.1 ex_857063.htm EX-32.1 8390
  Complete submission text file 0001437749-25-035191.txt   5918406

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA gnpx-20250930.xsd EX-101.SCH 47117
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE gnpx-20250930_cal.xml EX-101.CAL 19134
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE gnpx-20250930_def.xml EX-101.DEF 341540
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE gnpx-20250930_lab.xml EX-101.LAB 319775
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gnpx-20250930_pre.xml EX-101.PRE 362357
52 EXTRACTED XBRL INSTANCE DOCUMENT gnpx20250930_10q_htm.xml XML 912348
Mailing Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712
Business Address 1601 TRINITY STREET, BLDG. B SUITE 3.322 AUSTIN TX 78712 512-537-7997
Genprex, Inc. (Filer) CIK: 0001595248 (see all company filings)

EIN.: 900772347 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38244 | Film No.: 251486245
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)